Funding
Dutch life sciences company FlexGen, a specialist in a custom microarray synthesis equipment, has closed a new round of funding, allowing it to speed up the development and commercialisation of FlexArrayer.
FlexGen is collaborating with several scientific and industrial customers and partners to apply its technology to next-generation genome sequencing, biomarker validation and other areas.
Fred Dom, CEO of FlexGen said, “The rapidly growing use of next-generation sequencing has created exciting opportunities for FlexGen. With the support of our new investors we are able to take a strong position in this growing market. FlexArrayer provides fast and flexible tools for genomic selection and biomarker validation that can easily be integrated in the high throughput approaches that sequencing facilities require.”
FlexGen has developed proprietary technologies in custom microarray production based on the use of lasers in spot-by-spot photochemical oligonucleotide synthesis. The company was founded in 2004, by VenGen Participaties bv and TailWind bv.
The technology was originally developed by Dutch Space NV and Leiden University Medical Centre with the support of BioPartner and the Netherlands Genomics Initiative.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
